- Home
- BC vs ACAD Comparison
BC vs ACAD Comparison
Compare BC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BC
- ACAD
- Stock Information
- Founded
- BC 1845
- ACAD 1993
- Country
- BC United States
- ACAD United States
- Employees
- BC N/A
- ACAD N/A
- Industry
- BC Homebuilding
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- BC Consumer Discretionary
- ACAD Health Care
- Exchange
- BC Nasdaq
- ACAD Nasdaq
- Market Cap
- BC 3.6B
- ACAD 3.8B
- IPO Year
- BC N/A
- ACAD 2004
- Fundamental
- Price
- BC $59.89
- ACAD $21.24
- Analyst Decision
- BC Buy
- ACAD Buy
- Analyst Count
- BC 13
- ACAD 19
- Target Price
- BC $71.54
- ACAD $27.89
- AVG Volume (30 Days)
- BC 1.0M
- ACAD 2.0M
- Earning Date
- BC 07-24-2025
- ACAD 08-05-2025
- Dividend Yield
- BC 2.87%
- ACAD N/A
- EPS Growth
- BC N/A
- ACAD N/A
- EPS
- BC 1.22
- ACAD 1.37
- Revenue
- BC $5,093,900,000.00
- ACAD $996,283,000.00
- Revenue This Year
- BC N/A
- ACAD $13.39
- Revenue Next Year
- BC $5.63
- ACAD $10.59
- P/E Ratio
- BC $49.07
- ACAD $15.51
- Revenue Growth
- BC N/A
- ACAD 22.42
- 52 Week Low
- BC $41.00
- ACAD $13.40
- 52 Week High
- BC $87.65
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- BC 66.56
- ACAD 47.26
- Support Level
- BC $54.73
- ACAD $21.16
- Resistance Level
- BC $56.33
- ACAD $23.09
- Average True Range (ATR)
- BC 1.87
- ACAD 0.81
- MACD
- BC 0.06
- ACAD -0.31
- Stochastic Oscillator
- BC 97.60
- ACAD 3.85
About BC Brunswick Corporation
Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns numerous Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.